Cresco Labs Inc.
No enriched coverage for $CRLBF in the last 7 days.
No SEC Form 4 filings for $CRLBF in the last 30 days.
Simply Wall St reports Cresco Labs’ Q2 results shifted to profitability, with revenue of US$173.3m (vs. US$166.1m), net income of US$16.8m (vs. a US$16.3m loss), and basic EPS of US$0.045. Adjusted EBITDA was US$40m, with a 22.8% margin and 51.6% adjusted gross margin. Operating cash flow was US$15m vs capex US$9m, while management guided Q3 EBITDA margin near 20%.
Cresco Labs Inc. (OTCMKTS:CRLBF) shares rose 3.6% to $0.9498 after trading as high as $0.98 on Monday; the article says 476,660 shares changed hands, down 31% from average volume. Zacks upgraded the stock from “strong sell” to “hold.” For the quarter ended May 8, EPS was -$0.04 vs -$0.03 estimate on revenue of $151.33M vs $148.58M.
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -33.33% and 0.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Recent CRLBF coverage spans financial news, earnings and market movers.
Simply Wall St reports Cresco Labs’ Q2 results shifted to profitability, with revenue of US$173.3m (vs. US$166.1m), net income of US$16.8m (vs. a US$16.3m loss), and basic EPS of US$0.045. Adjusted EBITDA was US$40m, with a 22.8% margin and 51.6% adjusted gross margin. Operating cash flow was US$15m vs capex US$9m, while management guided Q3 EBITDA margin near 20%.
The move is framed as sentiment/analyst-driven rather than a new fundamental catalyst; near-term focus shifts to earnings trajectory and rating support.
Cresco Labs Inc. reported a Q1 loss of 33.33% worse than expected but slightly exceeded revenue estimates by 0.84%. The negative earnings surprise indicates operational challenges, but the slight revenue beat suggests some resilience.
Cresco Labs shares rose 15.52%, reflecting positive market sentiment and investor confidence.
alphai scores every news story that mentions CRLBF with an AI model for sentiment and relevance, and aggregates insider trades from Cresco Labs Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Simply Wall St reports Cresco Labs’ Q2 results shifted to profitability, with revenue of US$173.3m (vs. US$166.1m), net income of US$16.8m (vs. a US$16.3m loss), and basic EPS of US$0.045. Adjusted EBITDA was US$40m, with a 22.8% margin and 51.6% adjusted gross margin. Operating cash flow was US$15m vs capex US$9m, while management guided Q3 EBITDA margin near 20%.
6 min readCresco Labs Inc. (OTCMKTS:CRLBF) shares rose 3.6% to $0.9498 after trading as high as $0.98 on Monday; the article says 476,660 shares changed hands, down 31% from average volume. Zacks upgraded the stock from “strong sell” to “hold.” For the quarter ended May 8, EPS was -$0.04 vs -$0.03 estimate on revenue of $151.33M vs $148.58M.
4 min readCresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -33.33% and 0.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readCuraleaf Holdings CURLF shares closed up 19.72% at $1.08 Cresco Labs CRLBF shares closed up 15.52% at $0.97 FLUENT CNTMF shares closed up 15.38% at $0.06 Global Hemp Group GBHPF shares closed up 14.45% at $0.01 Urban-gro UGRO shares closed up 14.27% at $0.45
4 min read
